Allergan said it will buy MAP Pharmaceuticals in a $958 million deal that would help the Botox maker expand sales of medical treatments.
Allergan to buy MAP for $958 million
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.